HPS-157 - The impact of Nintedanib related adverse effects on clinical outcomes in patients with idiopathic pulmonary fibrosis: An analysis of preliminary

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-157
• By: CHANG, Yuwen (Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, China Taiwan)
• Co-author(s): Ms Yuwen Chang (Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, China Taiwan)
  mr Chengchih Wu (Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, China Taiwan)
  
• Abstract:

  PURPOSE: Nintedanib is an intracellular inhibitor of tyrosine kinases that inhibits the progression of pulmonary fibrosis. However, treatment discontinuation due to nintedanib related adverse drug reaction (ADR) is common. The aim of this study was to explord real-world tolerability of nintedanib with 12- month follow up in Taiwan.
  METHODS: This..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login